Gregg Gilbert

In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert reiterated a Buy rating and $65.00 price target on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). In the report, Deutsche Bank noted, “TEVA announced a final approval for its generic version of Nexium, a $2bn product (reported US...

Deutsche Bank and Stifel took differing positions on Eli Lilly and Co (NYSE: LLY) Thursday. Analyst Gregg Gilbert at Deutsche Bank downgraded the stock from Buy to Hold and maintained a $75 price target. Gilbert felt the stock had performed well in 2014, but little upside remained. “...

In a report published Thursday, Deutsche Bank analyst Gregg Gilbert downgraded the rating on Eli Lilly and Co (NYSE: LLY) from Buy to Hold, but reiterated the $75.00 price target. In the report, Deutsche Bank noted, “For a few years we have been contrarian bulls on LLY based on what we...

In a report published Tuesday, Deutsche Bank analyst Gregg Gilbert initiated coverage on Ligand Pharmaceuticals Inc. (NASDAQ: LGND) with a Buy rating and $74.00 price target. In the report, Deutsche Bank noted, “We are initiating coverage of Ligand with a Buy rating and $74 target price. We view...

Deutsche Bank cut its price target Sunday on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) from $134 to $102 and maintained a Hold rating. Analyst Gregg Gilbert noted that "following SLXP’s 3Q miss and disclosures about excessive wholesaler inventory levels for its key products, we...

Deutsche Bank initiated coverage of Allergan, Inc (NYSE: AGN) in a report issued Wednesday with a Buy Rating and price target of $215. Analyst Gregg Gilbert viewed Allergan as a “best-in-class Specialty Pharma company, with an attractive combination of strong and sustainable organic...

Gregg Gilbert of Deutsche Bank initiated coverage of Pfizer (NYSE: PFE) on Wednesday with a Buy rating and $34 price target. “While Pfizer continues to face headwinds to top-line growth and has a less obviously compelling pipeline relative to some of its peers, we like the company's...

Deutsche Bank initiated coverage of Merck (NYSE: MRK) with a Hold rating and price target of $63. Analyst Gregg Gilbert outlined reasons for the initiation: Merck has established base businesses, with a track record of returning cash to shareholders. Merck has potential multi-billion...

In a report published Friday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $56.00 to $58.00. In the report, Bank of America noted, “ABBV is unique among the US Major Pharma companies given its significant product...

In a report published Wednesday, Bank of America analyst Gregg Gilbert reiterated a Buy rating on Actavis (NYSE: ACT), and raised the price target from $200.00 to $235.00. In the report, Bank of America noted, “We updated our model to reflect ACT's proposed acquisition of Forest (both boards...

In a report published Friday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Neutral to Buy and lowered the price target from $26.00 to $25.00 noting favorable risk-reward on the stock's pullback. Gilbert commented on the limited downside if...

In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Perrigo (NYSE: PRGO) to Buy from Neutral, raising its price objective to $171.00 from $162.00. According to the report, PRGO is the leader in OTC store brands and a strong participant in generic topicals....

In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert downgraded Salix Pharmaceuticals (NASDAQ: SLXP) to Underperform from Neutral, keeping its $86.00 price objective. According to the report, SLXP's base business has been performing well, led by continued solix...

In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert reiterated a Buy rating on AbbVie (NYSE: ABBV), raising its price target from $53.00 to $56.00. According to the report, in light of recent positive trial results and a survey published by BofA's biotech team,...

In a report published on Monday, Bank of America analyst Gregg Gilbert upgraded Perrigo (NYSE: PRGO) from Underperform to Neutral and raised the price target on the company from $116 to $133. In the report, Bank of America stated, "PRGO announced that it will acquire Elan for $8.6bn in cash and...